A single-center retrospective observational study of dolutegravir plus lamivudine in people living with HIV.
Latest Information Update: 27 Dec 2022
At a glance
- Drugs Dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
Most Recent Events
- 27 Dec 2022 New trial record
- 01 Dec 2022 Results published in the AIDS Research and Human Retroviruses